METTL14 and glioblastoma: Notably, METTL14 has been reported to be required for some cancer development, whereas METTL14 activation shows more tumor‐suppressive activity in a variety of tumors including UCEC (Liu et al, 2018), LIHC (Ma et al, 2017), GBM (Cui et al, 2017), and skin cancer (Yang et al, 2021).